肝癌微创介入治疗进展  

Advances in minimally invasive interventional therapy for hepatocellular carcinoma

作　　者：吕天石[1] 邹英华[1] LYU Tian-shi;ZOU Ying-hua(Department of Interventional Radiology and Vascular Surgery, Peking University First Hospital, Beijing 100034, China)

机构地区：[1]北京大学第一医院介入血管外科,北京100034

出　　处：《中国临床新医学》2020年第3期211-215,共5页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

摘　　要：原发性肝癌的治疗方法一直是许多学者研究的重点,近年来尽管新兴治疗方法层出不穷,但由于病变多发生于进展期肝病或肝硬化的基础上,因此目前原发性肝癌仍然是一种难治性恶性肿瘤。在治疗方面,外科手术切除及肝移植虽是根治性治疗方法,但由于移植相关问题的复杂性及原发性肝癌本身的隐匿性,使得上述两种治疗方法并不能适用于大多数患者。近些年,随着设备和技术水平的提高,原发性肝癌的微创介入治疗得到了越来越多的重视,其中应用最为广泛的就是肝动脉化疗栓塞术(TACE)和组织消融术(TA)。该文主要讨论上述两种介入疗法联合应用治疗原发性肝癌的有效性、可行性,以及近年来介入治疗在原发性肝癌治疗领域的研究进展。The treatment of hepatocellular carcinoma(HCC)has always been the focus of many scholars.Despite the development of new therapies,HCC remains a“difficult to treat”cancer because HCC typically occurs in advanced liver disease or hepatic cirrhosis.In terms of treatment,although surgical resection and liver transplantation are radical treatments,the two treatments are not suitable for most patients due to the complexity of transplant-related problems and the occult nature of HCC.In recent years,with the improvement of equipment and technology,more and more attention has been paid to the minimally invasive interventional treatment of HCC,of which transarterial chemoembolization(TACE)and tissue ablation(TA)are the most widely used.In this paper,we mainly discuss the effectiveness and feasibility of the combination of the two kinds of interventional therapy in the treatment of HCC,as well as the research progress of interventional therapy in the field of HCC in recent years.

关 键 词：原发性肝癌 微创介入 联合治疗 研究进展 

分 类 号：R735.7[医药卫生—肿瘤]